This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gandhi, V. Articles by Plunkett, W. Search for Related Content PubMed PubMed Citation Articles by Gandhi, V. Articles by Plunkett, W.

Modulation of Arabinosylnucleoside Metabolism by Arabinosylnucleotides in Human Leukemia Cells¹

Department of Medical Oncology, The University of Texas, M. D. Anderson Hospital and Tumor Institute at Houston, Houston, Texas 77030

Previous studies have indicated that deoxycytidine kinase (dCK) is requisite and rate limiting in the phosphorylation of 1-ß-D-arabinofuranosylcytosine (ara-C) and 9-ß-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) on the pathway to their respective cytotoxic 5'-triphosphates. In K562 cells, the rate of triphosphate accumulation was maximal during incubation with 10 µM ara-C (35 µM/h) and 300 µM F-ara-A (102 µM/h). Under these conditions, accumulation of cellular ara-CTP plateaued at about 110 µM after 3 h, whereas in separate cultures, F-ara-ATP continued to accumulate at a linear rate to cellular concentrations greater than 500 µM after 5 h. Other laboratories have demonstrated that dCK activity in cell-free extracts was inhibited by ara-CTP. To determine whether ara-CTP exhibited the same activity in whole cells, K562 cells were preincubated with ara-C to accumulate 110 µM ara-CTP. After washing into medium containing F-ara-A, the rate of F-ara-ATP accumulation was significantly decreased (37 µM/h). However, cells loaded with F-ara-ATP exhibited an increased rate of ara-CTP accumulation (110 µM/h) that resulted in cellular ara-CTP concentrations in excess of 400 µM after 5 h. This stimulation was proportional to the cellular concentration of F-ara-ATP, achieving a maximum effect between 75 and 100 µM. Phosphorylation of ara-C by cell-free extracts supplemented with physiological levels of ribo- and deoxyribonucleoside 5'-triphosphates was stimulated by addition of F-ara-ATP. The decreased rate of accumulation of products of dCK in intact cells containing 110 µM ara-CTP suggests that this active triphosphate may limit its own synthesis and phosphorylation of other substrates. In contrast, stimulation of the accumulation of ara-CTP in cells containing F-ara-ATP suggests new possibilities for the design of combination chemotherapy regimens.

¹ Supported in part by Grant CA 28596 from the National Cancer Institute, Department of Health and Human Services, and Grant CH-130 from the American Cancer Society.

² To whom requests for reprints should be addressed, at Department of Medical Oncology, The University of Texas, M. D. Anderson Hospital and Tumor Institute at Houston, 1515 Holcombe Blvd., P. O. Box 52, Houston, TX 77030.

Received 2/25/87. Revised 6/ 3/87. Revised 9/30/87. Accepted 10/19/87.

This article has been cited by other articles:

				R. B. Klisovic, W. Blum, X. Wei, S. Liu, Z. Liu, Z. Xie, T. Vukosavljevic, C. Kefauver, L. Huynh, J. Pang, et al. Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia Clin. Cancer Res., June 15, 2008; 14(12): 3889 - 3895. [Abstract] [Full Text] [PDF]

				D. F Kisor Nelarabine: A Nucleoside Analog with Efficacy in T-Cell and Other Leukemias Ann. Pharmacother., June 1, 2005; 39(6): 1056 - 1063. [Abstract] [Full Text] [PDF]

				S. Faderl, V. Gandhi, S. O'Brien, P. Bonate, J. Cortes, E. Estey, M. Beran, W. Wierda, G. Garcia-Manero, A. Ferrajoli, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias Blood, February 1, 2005; 105(3): 940 - 947. [Abstract] [Full Text] [PDF]

				K. R. Crews, V. Gandhi, D. K. Srivastava, B. I. Razzouk, X. Tong, F. G. Behm, W. Plunkett, S. C. Raimondi, C.-H. Pui, J. E. Rubnitz, et al. Interim Comparison of a Continuous Infusion Versus a Short Daily Infusion of Cytarabine Given in Combination With Cladribine for Pediatric Acute Myeloid Leukemia J. Clin. Oncol., October 15, 2002; 20(20): 4217 - 4224. [Abstract] [Full Text] [PDF]

				V. Gandhi, W. Plunkett, S. Weller, M. Du, M. Ayres, C. O. Rodriguez Jr, P. Ramakrishna, G. L. Rosner, J. P. Hodge, S. O'Brien, et al. Evaluation of the Combination of Nelarabine and Fludarabine in Leukemias: Clinical Response, Pharmacokinetics, and Pharmacodynamics in Leukemia Cells J. Clin. Oncol., April 15, 2001; 19(8): 2142 - 2152. [Abstract] [Full Text] [PDF]

				H. Iwasaki, P. Huang, M. J. Keating, and W. Plunkett Differential Incorporation of Ara-C, Gemcitabine, and Fludarabine Into Replicating and Repairing DNA in Proliferating Human Leukemia Cells Blood, July 1, 1997; 90(1): 270 - 278. [Abstract] [Full Text] [PDF]

				K.-i. Kamiya, P. Huang, and W. Plunkett Inhibition of the 3' right-arrow 5' Exonuclease of Human DNA Polymerase epsilon by Fludarabine-terminated DNA J. Biol. Chem., August 9, 1996; 271(32): 19428 - 19435. [Abstract] [Full Text] [PDF]